1. Home
  2. ARGX vs VLO Comparison

ARGX vs VLO Comparison

Compare ARGX & VLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • VLO
  • Stock Information
  • Founded
  • ARGX 2008
  • VLO 1980
  • Country
  • ARGX Netherlands
  • VLO United States
  • Employees
  • ARGX N/A
  • VLO N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • VLO Integrated oil Companies
  • Sector
  • ARGX Health Care
  • VLO Energy
  • Exchange
  • ARGX Nasdaq
  • VLO Nasdaq
  • Market Cap
  • ARGX 44.2B
  • VLO 45.3B
  • IPO Year
  • ARGX 2017
  • VLO N/A
  • Fundamental
  • Price
  • ARGX $756.83
  • VLO $157.57
  • Analyst Decision
  • ARGX Strong Buy
  • VLO Buy
  • Analyst Count
  • ARGX 19
  • VLO 15
  • Target Price
  • ARGX $777.83
  • VLO $160.50
  • AVG Volume (30 Days)
  • ARGX 360.8K
  • VLO 2.4M
  • Earning Date
  • ARGX 10-30-2025
  • VLO 10-23-2025
  • Dividend Yield
  • ARGX N/A
  • VLO 2.87%
  • EPS Growth
  • ARGX N/A
  • VLO N/A
  • EPS
  • ARGX 18.75
  • VLO 2.41
  • Revenue
  • ARGX $3,120,821,000.00
  • VLO $117,549,000,000.00
  • Revenue This Year
  • ARGX $80.01
  • VLO N/A
  • Revenue Next Year
  • ARGX $30.64
  • VLO N/A
  • P/E Ratio
  • ARGX $35.87
  • VLO $65.27
  • Revenue Growth
  • ARGX 88.04
  • VLO N/A
  • 52 Week Low
  • ARGX $510.06
  • VLO $99.00
  • 52 Week High
  • ARGX $779.03
  • VLO $163.02
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 74.39
  • VLO 67.09
  • Support Level
  • ARGX $745.82
  • VLO $153.60
  • Resistance Level
  • ARGX $779.03
  • VLO $163.02
  • Average True Range (ATR)
  • ARGX 14.92
  • VLO 3.99
  • MACD
  • ARGX 1.39
  • VLO 0.38
  • Stochastic Oscillator
  • ARGX 74.14
  • VLO 69.52

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

About VLO Valero Energy Corporation

Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.

Share on Social Networks: